✉ Email this page to a colleague
« Back to Dashboard
Lapaquistat is an investigational drug.
There have been 16 clinical trials for Lapaquistat. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2005.
The most common disease conditions in clinical trials are Hypercholesterolemia, Dyslipidemias, and Hyperlipoproteinemia Type II. The leading clinical trial sponsors are Takeda and [disabled in preview].
Recent Clinical Trials for Lapaquistat
|Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia||Takeda||Phase 3|
|Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia||Takeda||Phase 3|
|Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia||Takeda||Phase 2|